Puma Biotechnology (PBYI)
Commercializes NERLYNX for HER2-positive breast cancer and develops alisertib.
$9.69
Pre-market−0.01 (−0.05%)
At close$9.70(+3.69%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56 | 72 | 44 | 47 | 81 | 59 | 46 | 52 | 54 | 75 | 45 | 57 |
| Cost of revenue | 13 | 24 | 11 | 11 | 29 | 14 | 11 | 12 | 12 | 23 | 10 | 12 |
| Gross profit | 43 | 48 | 33 | 36 | 51 | 45 | 35 | 40 | 42 | 52 | 34 | 44 |
| 34 | 33 | 35 | 39 | 29 | 32 | 31 | 33 | 33 | 35 | 38 | 36 | |
| Research & development | 11 | 13 | 14 | 14 | 13 | 15 | 14 | 15 | 16 | 17 | 20 | 19 |
| 22 | 20 | 22 | 25 | 17 | 17 | 17 | 18 | 17 | 18 | 18 | 18 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 22 | 20 | 22 | 25 | 17 | 17 | 17 | 18 | 17 | 18 | 18 | 18 |
| Other expenses | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 9 | 15 | −2 | −2 | 22 | 13 | 4 | 7 | 10 | 17 | −4 | 8 |
| −3 | −2 | −2 | −2 | −1 | −1 | −1 | 0 | 0 | 0 | 0 | 1 | |
| Interest income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest expense | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 0 |
| Other non-operating income | 0 | −1 | −1 | −1 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| Income before tax | 6 | 13 | −5 | −4 | 21 | 12 | 3 | 6 | 9 | 17 | −3 | 8 |
| Income tax expense | 0 | 1 | 0 | 0 | 0 | −7 | 0 | 0 | 0 | 4 | 0 | 0 |
| Net income from continuing operations | 6 | 12 | −5 | −5 | 20 | 19 | 3 | 6 | 9 | 13 | −4 | 8 |
| Net income | 6 | 12 | −5 | −5 | 20 | 19 | 3 | 6 | 9 | 13 | −4 | 8 |
| EPS, basic | $0.12 | $0.26 | −$0.10 | −$0.09 | $0.41 | $0.39 | $0.06 | $0.12 | $0.18 | $0.27 | −$0.07 | $0.16 |
| EPS, diluted | $0.12 | $0.26 | −$0.10 | −$0.09 | $0.41 | $0.39 | $0.06 | $0.12 | $0.17 | $0.26 | −$0.07 | $0.16 |
| Weighted average shares, basic | 48 | 48 | 48 | 48 | 49 | 49 | 50 | 50 | 50 | 50 | 51 | 51 |
| Weighted average shares, diluted | 48 | 48 | 48 | 48 | 49 | 49 | 50 | 50 | 51 | 52 | 51 | 53 |
| EBITDA | 11 | 18 | 2 | 2 | 27 | 18 | 8 | 11 | 13 | 21 | 0 | 14 |
| Depreciation & amortization | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 |
| EBIT | 9 | 15 | −1 | −1 | 24 | 15 | 5 | 8 | 11 | 18 | −3 | 8 |